Latest News

The global manufacturer of HYPURIN Porcine has stopped producing vial presentations, but the product will still be available in cartridge form, which requires a pen for administration. ​ Aspen has been managing access to HYPURIN Porcine products through the Special Access Scheme (SAS) for years and is now transferring full management to HL Pharma Pty Ltd. HL Pharma will provide a streamlined service with a focus on personalised care. ​ This change will take effect on 1 October 2025. ​

Click here to read/download the letter from Aspen Australia

A change in the Motor Vehicles Regulations came into effect on 7th November 2025 and it specifically affects lorry and bus (Group 2) drivers who have diabetes treated with insulin.

Click here for more information

At least 55,000 people will need repeat blood tests after errors were discovered in machines used to diagnose Type 2 diabetes. NHS England has confirmed that up to 10% of NHS laboratories in England have been affected by the errors in the HbA1c machines used to diagnose Type 2 diabetes. The effects of this mean that some people have been wrongly diagnosed with Type 2 diabetes and some have been prescribed unnecessary medication.

Click here for more details

Millions of people are set to benefit from earlier access to newer Type 2 diabetes treatments as part of NICE’s commitment to the 10-Year Health Plan for the NHS. The draft guidelines from NICE moves away from a ‘one-size-fits-all’ approach, shifting from automatically starting everyone on one medicine to personalised treatment plans that aim to prevent heart failure, heart attacks and other serious medical problems.

Click here for more details

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved teplizumab (called Tzield) as the UK’s first immunotherapy for Type 1 diabetes. The drug is licensed for adults and children aged 8 years or older with stage 2 Type 1 diabetes to delay progression to stage 3.

Click here for more details

On August 5th 2025, the National Institute for Health and Care Excellence (NICE) released updated guidance recommending that healthcare providers offer structured, ongoing support to patients after they complete obesity treatment or stop taking weight-loss medications.

Research shows that many people regain weight after stopping treatment if they don’t get the right help, which can negatively affect both their physical and mental health.

Click here for more details

The JCVI have stated that there is now a high population immunity to COVID-19, additional COVID-19 doses provide very limited, if any, protection against infection and any subsequent onward transmission of infection.

In the UK, the government has therefore decided that, from Autumn 2025, only the following groups of people will be offered a COVID-19 vaccination:

• adults aged 75 years and over
• residents in a care home for older adults
• people aged 6 months and over who are immunosuppressed (for more information see the NHS website: COVID-19 vaccine – NHS)

Click here for more details

On 5th June 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) issued a press release to remind women with diabetes also taking the popular medicines for weight loss to use safe and effective contraception. In some cases, it is advised that women stop the medication at least two months before trying to get pregnant.

The GLP-1 medicines brand names include Ozempic, Mounjaro, Wegovy, Saxenda and Victoza and the key points are
Click here for more details

Department of Health and Social Care (DHSC) is aware of these discontinuations and has already issued Medicines Supply Notifications to healthcare professionals for some of them.

• NovoRapid FlexTouch is being discontinued in March 2025
• Insulatard Penfill 100units/ml 3ml cartridges are being discontinued
• Levemir is being discontinued

Click here for more details

IDDT donates to children in a Ukrainian orphanage

The Medicines and Healthcare products Regulatory Agency (MHRA) is asking patients who use a continuous glucose monitor (CGM) or insulin pump to report any safety problem with their device through the MHRA Yellow Card scheme without delay.

Please click here to read more about this release

Although it is still only Autumn, the flu season is coming and people with diabetes are at increased risk of developing complications of flu and difficulties with the impact flu may have on their diabetes. Flu is a respiratory virus and causes symptoms such as fever, cough, sore throat, runny nose and can progress to more serious illnesses, such as pneumonia.

Please click here to read more about ‘flu, and how it can affect people with diabetes

IMPORTANT PRODUCT INFORMATION
(AutoPen Classic supplied by Owen Mumford)

You may be aware that Owen Mumford plan to discontinue their AutoPen Classic reusable, insulin delivery pens which are compatible with our following Hypurin (porcine insulin) products:

• Hypurin Porcine 30/70 Mix Cartridges – PL 29831/0119
• Hypurin Porcine Isophane Cartridges – PL 29831/0122
• Hypurin Porcine Neutral Cartridges – PL 29831/0124

Please note there is no immediate need for patients currently using Autopen Classic insulin pens to change their devices.

Please click here to read more

The deepening crisis in Ukraine means that there is an increasingly desperate need to help people trying to live with diabetes. It is hard to believe that not only are the people of Ukraine having to fight for their country and freedom, but they also are in desperate need all their diabetes supplies. As the bombing continues, pharmacies close, hospitals run out of supplies and supply routes targeted.

Click here to read more

Update from Ukraine, July 2024

Thanks to the help of our members, healthcare professionals and many people who have become aware of the support we give to people with diabetes in Ukraine, we are still receiving lots of diabetes items.

Click here to read more

We value all of the feedback left by our members and we want to say THANK YOU for all of your lovely comments!

To receive your information pack, become a member here

NICE recommends life changing technology is rolled out to people with type 1 diabetes
An announcement of the recommendations was made on 7 November 2023 at NICE’s annual conference in Manchester by NICE chief executive Dr Sam Roberts.

Thousands of people with type 1 diabetes could be offered wearable technology to help them manage their condition following the publication of final draft guidance by NICE.

Click here to read more